Daniel Libby
Pulmonary Disease · New York, NYNPI 1114033057
Payments from drug & device makers
Across 192 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$969
- Boehringer Ingelheim$255
- Electromed, Inc.$227
- Actelion Pharmaceuticals US, Inc.$184
- Amgen$156
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,18497%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 76 | $1,353 |
| Insmed, Inc. | 37 | $969 |
| Boehringer Ingelheim | 9 | $255 |
| Electromed, Inc. | 11 | $227 |
| Actelion Pharmaceuticals US, Inc. | 7 | $184 |
| Amgen | 7 | $156 |
| AstraZeneca | 8 | $149 |
| Philips North America LLC | 5 | $143 |
| Pulmonx Corporation | 2 | $141 |
| Regeneron Healthcare Solutions, Inc. | 8 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $118 |
| Sanofi | 4 | $110 |
| Baxter Healthcare | 3 | $81 |
| Advanced Respiratory, Inc | 2 | $64 |
| Mylan Specialty L.p. | 1 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Merck | 2 | $33 |
| Novartis | 1 | $30 |
| Verona Pharma, Inc. | 1 | $30 |
| 3b Medical, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
How this compares
$4,294 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 16 | $425,442 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 282 | $204,666 |
| Dupixent PenDupilumab | 17 | $96,069 |
| Breo ElliptaFluticasone/Vilanterol | 111 | $44,043 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $38,327 |
| Spiriva HandihalerTiotropium Bromide | 19 | $25,414 |
| EliquisApixaban | 22 | $17,577 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $13,528 |
| XareltoRivaroxaban | 13 | $11,894 |
| Spiriva RespimatTiotropium Bromide | 11 | $9,075 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,442 |
| Atrovent HfaIpratropium Bromide | 11 | $5,025 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,597 |
| PaxlovidNirmatrelvir/Ritonavir | 20 | $4,287 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $4,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,353 | $292,477493 claims |
| AstraZenecaSymbicort | $149 | $13,52846 claims |
| Boehringer IngelheimSpiriva Respimat | $255 | $9,07511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Doreen Addrizzo-HarrisNew York$1.9M
- Emily DimangoNew York$1.4M
- da ZhangNew York$1.3M
- Claire KeatingNew York$1.2M
- Charles PowellNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.